GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » Scaled Net Operating Assets

ZNTL (Zentalis Pharmaceuticals) Scaled Net Operating Assets : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zentalis Pharmaceuticals's operating assets for the quarter that ended in Mar. 2025 was $51.57 Mil. Zentalis Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2025 was $49.99 Mil. Zentalis Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $430.34 Mil. Therefore, Zentalis Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2025 was 0.00.


Zentalis Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Zentalis Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentalis Pharmaceuticals Scaled Net Operating Assets Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial -0.04 0.19 0.09 - 0.01

Zentalis Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - 0.01 0.01 -

Competitive Comparison of Zentalis Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zentalis Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Scaled Net Operating Assets falls into.


;
;

Zentalis Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zentalis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(59.253-53.574)/551.688
=0.01

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=430.337 - 371.084
=59.253

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=93.151 - 39.577 - 0
=53.574

Zentalis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2025 )
=(Operating Assets (Q: Mar. 2025 )-Operating Liabilities (Q: Mar. 2025 ))/Total Assets (Q: Dec. 2024 )
=(51.568-49.988)/430.337
=0.00

where

Operating Assets(Q: Mar. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=384.021 - 332.453
=51.568

Operating Liabilities(Q: Mar. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=88.639 - 38.651 - 0
=49.988

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zentalis Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zentalis Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Executives
Andrea Paul officer: General Counsel 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman director C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Melissa B, Epperly officer: Chief Financial Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein officer: Chief Medical Officer 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Iris Roth officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Anthony Y Sun director, officer: President & CEO C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto officer: Chief Legal Officer C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis officer: SVP, Clinical Development C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901